Aditxt Inc
Research Aditxt Inc (ADTX) on Bullrun: market cap USD 232. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerADTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 232
- Financial periodQ1 2026
- RevenueUSD 12.16K
- Net income-USD 15.95M
- Free cash flow-USD 4.59M
- Gross margin23.6%
Valuation Snapshot
latest market cap is USD 232.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.20K | -USD 43.10M | -USD 25.70M | 8.4% | -1153.83 | USD 3.20M | USD 3.01M | USD 5.61M |
| FY2024 | USD 133.99K | -USD 40.35M | -USD 16.76M | -368.3% | -114967.05 | USD 833.03K | USD 6.92M | USD 1.67M |
| FY2023 | USD 645.18K | -USD 32.70M | -USD 19.22M | -17.3% | -27038.26 | USD 97.10K | USD 18.22M | USD 16.06M |
| FY2022 | USD 933.72K | -USD 27.65M | -USD 22.76M | 17.9% | -595.6 | USD 2.77M | USD 4.37M | USD 5.21M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 232 | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.48M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 4.29M | n/a | n/a | n/a |
About Aditxt Inc
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It develops ADI-100 for skin grafting, psoriasis, and type-1 diabetes.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Aditxt Inc's market cap?
Aditxt Inc's market capitalization is USD 232.
What does Aditxt Inc do?
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It develops ADI-100 for skin grafting, psoriasis, and type-1 diabetes.